Esperion Starts Phase 3 Study of Cholesterol-Fighter
ANN ARBOR — Esperion Therapeutics Inc. Monday announced the start of a Phase 3 study to assess the safety and efficacy of a combination pill containing its cholesterol-fighter, bempedoic acid, with ezetimibe, a drug that decreases cholesterol absorption in the small intestine. Ezetimibe is used when other cholesterol-lowering medications, such as statins, are not tolerated